SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eiko Lifesciences informs about newspaper publication

02 Jan 2024 Evaluate
Eiko Lifesciences has informed that a corrigendum to the advertisement in connection with the First and Final Call Notice is published in the following newspapers on 02nd January, 2024:   Business Standard, Mumbai Lakshadweep. They are submitting copy of e-clippings of the corrigendum published in above mentioned newspaper for records.

The above information is a part of company’s filings submitted to BSE.

Eiko Lifesciences Share Price

50.46 0.00 (0.00%)
04-May-2026 10:32 View Price Chart
Peers
Company Name CMP
BASF India 3715.85
Tata Chemicals 817.00
SRF 2536.55
Pidilite Inds. 1374.20
Deepak Nitrite 1735.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×